Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Raben

Showing results (111-120 of 161) with videos related to

Pageof 17
Sort By:
Plos One|September 18, 2012
The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiationRebecca E Oberley-Deegan, Joshua J Steffan, Kyle O Rove, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2007
A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patientsChristopher D Willey, Barbara A Murphy, James L Netterville, et al.
International Journal of Radiation Oncology, Biology, Physics|March 17, 2010
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancerKyle E Rusthoven, Steven J Feigenberg, David Raben, et al.
Journal of the National Cancer Institute|March 14, 2019
STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck CancerAyman J Oweida, Laurel Darragh, Andy Phan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2016
Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trialRaquibul Hannan, Vasu Tumati, Xian-Jin Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell CarcinomaThomas J Galloway, Lori J Wirth, Alexander D Colevas, et al.
Molecular Carcinogenesis|December 22, 2018
Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomasAriel L Hernandez, Ying Wang, Hilary L Somerset, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancerCataldo Bianco, Elisa Giovannetti, Fortunato Ciardiello, et al.
Cancer Research|October 10, 2014
Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancersGregory N Gan, Justin Eagles, Stephen B Keysar, et al.
Cancer Research|August 17, 2006
Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplificationBrian L Rothschild, Ann H Shim, Amanda Gatesman Ammer, et al.
Pageof 17

Showing results (111-120 of 161) with videos related to

Sort By:
Pageof 17
Plos One|September 18, 2012
The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiationRebecca E Oberley-Deegan, Joshua J Steffan, Kyle O Rove, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2007
A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patientsChristopher D Willey, Barbara A Murphy, James L Netterville, et al.
International Journal of Radiation Oncology, Biology, Physics|March 17, 2010
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancerKyle E Rusthoven, Steven J Feigenberg, David Raben, et al.
Journal of the National Cancer Institute|March 14, 2019
STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck CancerAyman J Oweida, Laurel Darragh, Andy Phan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2016
Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trialRaquibul Hannan, Vasu Tumati, Xian-Jin Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell CarcinomaThomas J Galloway, Lori J Wirth, Alexander D Colevas, et al.
Molecular Carcinogenesis|December 22, 2018
Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomasAriel L Hernandez, Ying Wang, Hilary L Somerset, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancerCataldo Bianco, Elisa Giovannetti, Fortunato Ciardiello, et al.
Cancer Research|October 10, 2014
Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancersGregory N Gan, Justin Eagles, Stephen B Keysar, et al.
Cancer Research|August 17, 2006
Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplificationBrian L Rothschild, Ann H Shim, Amanda Gatesman Ammer, et al.
Pageof 17